Emergence Therapeutics Announces a Bumped-up Follow-on Seed Round Financing
Financing enables company to embark on additional targets and expand ADC technology reach
pixabay.com
"We are grateful for the continued support from our investors at this seed stage. The proceeds from the Follow-on Seed Round will be used to continue the development of our lead program targeting Nectin-4, an increasingly important and clinically validated target for a broad range of cancers. Moreover, the funding enables us to expedite work on further programs as well as expand our ADC toolset with additional, highly innovative linker-payload technologies", said Jack Elands, CEO of Emergence Therapeutics.
"We are particularly impressed with the approach Emergence Therapeutics is taking towards developing novel, much needed cancer treatments. The company features a unique combination of ADC technology driven by innovation and led by a world-class management team", said Dr. Anke Caßing, Senior Investment Manager at High-Tech Gründerfonds.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.